BRISTOL-MYERS SQUIBB COMPANY Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 0.00 shares.
- BRISTOL-MYERS SQUIBB COMPANY antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 0.00 shares.
- BRISTOL-MYERS SQUIBB COMPANY antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 21.00M shares, a 16.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 38.00M shares.
- BRISTOL-MYERS SQUIBB COMPANY antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 0.00 shares.
- BRISTOL-MYERS SQUIBB COMPANY antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 0.00 shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-07-30 | 0.00 shares 10-Q · filed 2026-07-30 | ||||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-04-30 | |||||
| 2025-12-31 | 0.00 shares 10-K · filed 2026-02-11 | |||||
| 2025-09-30 | 21.00M shares 10-Q · filed 2025-10-30 | 18.00M shares 10-Q · filed 2025-10-30 | ||||
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-07-30 | 23.00M shares 10-Q · filed 2025-07-31 | 0.00 shares 10-Q · filed 2026-07-30 | 19.00M shares 10-Q · filed 2025-07-31 | ||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-04-30 | |||||
| 2024-12-31 | 38.00M shares 10-K · filed 2026-02-11 | |||||
| 2024-09-30 | 25.00M shares 10-Q · filed 2025-10-30 | 41.00M shares 10-Q · filed 2025-10-30 | ||||
| 2024-06-30 | 39.00M shares 10-Q · filed 2025-07-31 | 44.00M shares 10-Q · filed 2025-07-31 | ||||
| 2024-03-31 | 46.00M shares 10-Q · filed 2025-04-24 | |||||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-11 | |||||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-10-31 | 0.00 shares 10-Q · filed 2024-10-31 | ||||
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-07-26 | 0.00 shares 10-Q · filed 2024-07-26 | ||||
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-04-25 | |||||
| 2022-12-31 | 0.00 shares 10-K · filed 2023-02-14 | |||||
| 2021-12-31 | 0.00 shares 10-K · filed 2023-02-14 | |||||
| 2021-09-30 | 8.00M shares 10-Q · filed 2021-10-27 | 9.00M shares 10-Q · filed 2021-10-27 | ||||
| 2021-06-30 | 9.00M shares 10-Q · filed 2021-07-28 | 9.00M shares 10-Q · filed 2021-07-28 | ||||
| 2021-03-31 | 14.00M shares 10-Q · filed 2021-04-29 | |||||
| 2020-12-31 | 106.00M shares 10-K · filed 2023-02-14 | |||||
| 2020-09-30 | 27.00M shares 10-Q · filed 2021-10-27 | 29.00M shares 10-Q · filed 2021-10-27 | ||||
| 2020-06-30 | 127.00M shares 10-Q · filed 2021-07-28 | 127.00M shares 10-Q · filed 2021-07-28 | ||||
| 2020-03-31 | 138.00M shares 10-Q · filed 2021-04-29 | |||||
| 2015-06-30 | 10.00M shares 10-Q · filed 2016-07-28 | |||||
| 2013-03-31 | 1.00M shares 10-Q · filed 2014-04-29 | |||||
| 2012-12-31 | 2.00M shares 10-K · filed 2015-02-13 | |||||
| 2012-09-30 | 2.00M shares 10-Q · filed 2013-10-23 | |||||
| 2012-06-30 | 3.00M shares 10-Q · filed 2013-07-25 | |||||
| 2012-03-31 | 7.00M shares 10-Q · filed 2013-04-25 | |||||
| 2011-12-31 | 13.00M shares 10-K · filed 2014-02-14 | |||||
| 2011-09-30 | 11.00M shares 10-Q · filed 2012-10-24 | 28.00M shares 10-Q · filed 2012-10-24 | ||||
| 2011-06-30 | 27.00M shares 10-Q · filed 2012-07-25 | 39.00M shares 10-Q · filed 2012-07-25 | ||||
| 2011-03-31 | 43.00M shares 10-Q · filed 2012-04-26 | |||||
| 2010-12-31 | 51.00M shares 10-K · filed 2013-02-15 | |||||
| 2010-09-30 | 48.00M shares 10-Q · filed 2011-10-27 | 64.00M shares 10-Q · filed 2011-10-27 | ||||
| 2010-06-30 | 64.00M shares 10-Q · filed 2011-07-28 | 66.00M shares 10-Q · filed 2011-07-28 | ||||
| 2010-03-31 | 70.00M shares 10-Q · filed 2011-04-28 | |||||
| 2009-12-31 | 117.00M shares 10-K · filed 2012-02-17 | |||||
| 2008-12-31 | 139.00M shares 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |